We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Early Treatment Prevents Future Childhood Virus

By HospiMedica staff writers
Posted on 27 Jun 2002
A study has found that a short-term treatment to prevent respiratory syncytial virus (RSV) in premature infants with lung disease not only prevented RSV during their first winter but also provided significant respiratory and immunologic benefits up to 10 years later. More...
The findings were reported in the June 2002 issue of The American Journal of Medicine.

The children in the study were born 10-11 weeks prematurely and had spent weeks in intensive care and on ventilators. Their compromised lungs made them especially susceptible to RSV infection. During their first winter, 13 received monthly injections of an immune globulin preparation with antibodies to RSV, which was effective in preventing RSV infection that winter. Seven to 10 years later, the researchers compared the 13 to 26 similar children, also premature infants with lung diseases, who had not received the preventive treatment. They found that more than 80% (21/26) of the control group had contracted an RSV infection, compared to only 15% (2/13) of the children who had received the immune globulin. Children in the RSV prevention group also had fewer asthma attacks than children in the control group.

The study was conducted by researchers at the National Jewish Medical and Research Center, the University of Colorado Health Sciences Center, and the Children's Hospital , all in Denver (CO, USA).

"Preventing these premature infants from contracting an RSV infection during their first winter had long-term benefits for their health,” said Sally Wenzel, M.D., co-author of the study and professor of medicine at National Jewish. "They have better lung function, and fewer colds, asthma attacks, and allergies.”


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Hemostatic Agent
HEMOBLAST Bellows
Neonatal Ventilator Simulation Device
Disposable Infant Test Lung
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.